2025
Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction.
Croon P, Dhingra L, Biswas D, Oikonomou E, Khera R. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Circulation 2025 PMID: 40888124, DOI: 10.1161/circulationaha.125.076279.Peer-Reviewed Original ResearchElectronic health recordsNon-cardiovascular conditionsPhenome-wide association studyCross-sectional phenotypingNew-onset cardiovascular diseaseCardiovascular diseaseProspective cohort studyPhenotypic associationsHealth recordsLeft ventricular hypertrophyStructural heart diseaseAI-ECGAssociated with cardiovascular phenotypesPearson correlation coefficientDiagnosis codesCohort studyCardiovascular risk markersLogistic regressionAssociation studiesCardiovascular diagnosisMitral regurgitationAortic stenosisCardiovascular conditionsStudy populationDetection of LVSDTransforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges
Biswas D, Aminorroaya A, Croon P, Batinica B, Pedroso A, Khera R. Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges. Current Atherosclerosis Reports 2025, 27: 86. PMID: 40888973, DOI: 10.1007/s11883-025-01337-4.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseasePopulation health screeningPopulation-level screeningCardiovascular diseaseLow riskHealth screeningStandard risk factorsHospital-basedCardiovascular healthSubclinical coronary artery diseaseWorkflow integrationSingle-lead ECGPersonalized interventionsPatient outcomesDiverse populationsTraditional risk modelsECG interpretationRisk factorsAscertainment biasImplementation challengesAdverse cardiovascular eventsProspective studyLogistical challengesRe-classifying patientsCoronary artery diseaseSHARING OF WEARABLE DATA WITH HEALTHCARE PROVIDERS AMONG US ADULTS WITH OR AT RISK FOR CARDIOVASCULAR DISEASE: A NATIONALLY REPRESENTATIVE ASSESSMENT
Camargos A, Dhingra L, Carter M, Aminorroaya A, Khera R. SHARING OF WEARABLE DATA WITH HEALTHCARE PROVIDERS AMONG US ADULTS WITH OR AT RISK FOR CARDIOVASCULAR DISEASE: A NATIONALLY REPRESENTATIVE ASSESSMENT. Journal Of The American College Of Cardiology 2025, 85: 2473. DOI: 10.1016/s0735-1097(25)02957-2.Peer-Reviewed Original ResearchControversy in Hypertension: Pro-Side of the Argument Using Artificial Intelligence for Hypertension Diagnosis and Management
Armoundas A, Ahmad F, Attia Z, Doudesis D, Khera R, Kyriakoulis K, Stergiou G, Tang W. Controversy in Hypertension: Pro-Side of the Argument Using Artificial Intelligence for Hypertension Diagnosis and Management. Hypertension 2025, 82: 929-944. PMID: 40091745, PMCID: PMC12094096, DOI: 10.1161/hypertensionaha.124.22349.Peer-Reviewed Original ResearchConceptsArtificial intelligenceHypertension diagnosisBlood pressure elevationRelationship to cardiovascular diseaseManagement of hypertensionLong-term managementArtificial intelligence-based solutionsPressure elevationPublic health challengeHypertensionArtificial intelligence scienceComplex pathogenesisClinical implementationCardiovascular diseaseState-of-artDiagnosisData-driven approachHypertension managementIntelligence scienceClinical adoptionArtificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association
Khera R, Asnani A, Krive J, Addison D, Zhu H, Vasbinder A, Fleming M, Arnaout R, Razavi P, Okwuosa T, Nursing O. Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation Genomic And Precision Medicine 2025, 18: e000097. PMID: 39989357, PMCID: PMC12316026, DOI: 10.1161/hcg.0000000000000097.Peer-Reviewed Original ResearchConceptsCardiovascular riskLong-term cardiovascular riskImmune checkpoint inhibitorsRisk of cardiovascular diseaseBiomarkers of riskCardio-oncology careHeightened risk of cardiovascular diseasePrevalence of cancerCheckpoint inhibitorsAmerican Heart AssociationCardiovascular risk managementTargeted therapyTherapeutic optionsCancer groupNovel therapiesHeightened riskHeart AssociationCardio-OncologyEnhancing precision medicineAdvanced imagingCardiovascular diseaseCancerDiagnostic testsTherapyPatients
2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, PMCID: PMC12045554, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelDesigning medical artificial intelligence systems for global use: focus on interoperability, scalability, and accessibility
Oikonomou E, Khera R. Designing medical artificial intelligence systems for global use: focus on interoperability, scalability, and accessibility. Hellenic Journal Of Cardiology 2024, 81: 9-17. PMID: 39025234, DOI: 10.1016/j.hjc.2024.07.003.Peer-Reviewed Original ResearchArtificial intelligenceMedical artificial intelligence systemsDesigning AI systemsMachine learning systemsArtificial intelligence systemsBenefits of AIIntelligent systemsAI systemsLearning systemEnd-usersData typesAI developmentInteroperabilityTemporal settingAccessScalabilityTreatment of cardiovascular diseasesIntelligenceSystemMachineQuality assuranceInternational cohortCardiovascular diseaseObstaclesPerformance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study
Camargos A, Barreto S, Brant L, Ribeiro A, Dhingra L, Aminorroaya A, Bittencourt M, Figueiredo R, Khera R. Performance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study. Open Heart 2024, 11: e002762. PMID: 38862252, PMCID: PMC11168182, DOI: 10.1136/openhrt-2024-002762.Peer-Reviewed Original ResearchConceptsPooled Cohort EquationsELSA-BrasilRisk scoreCardiovascular diseaseCVD eventsCommunity-based cohort studyArea under the receiver operating characteristic curveCVD risk scoreELSA-Brasil studyIncident CVD eventsMiddle-income countriesAdjudicated CVD eventsCardiovascular disease riskCVD scoreCohort EquationsNational guidelinesRisk stratification scoresWhite womenAge/sex groupsCohort studyProspective cohortLMICsSex/race groupsHigher incomeRisk discriminationData Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association
Armoundas A, Ahmad F, Bennett D, Chung M, Davis L, Dunn J, Narayan S, Slotwiner D, Wiley K, Khera R, Care P. Data Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation Genomic And Precision Medicine 2024, 17: e000095. PMID: 38779844, PMCID: PMC11703599, DOI: 10.1161/hcg.0000000000000095.Peer-Reviewed Original ResearchConceptsData interoperabilityDeployment of platformsInteroperability frameworkSoftware applicationsData integrationWearable devicesData ecosystemInteroperabilityMonitoring of cardiovascular diseasesQuality of dataDiverse health systemsClinical workflowTransform health careDataScientific statementCardiovascular diseaseClinical contentAmerican Heart AssociationCaregivers' accessHealth systemHealth careDevelopment and multinational validation of an algorithmic strategy for high Lp(a) screening
Aminorroaya A, Dhingra L, Oikonomou E, Saadatagah S, Thangaraj P, Vasisht Shankar S, Spatz E, Khera R. Development and multinational validation of an algorithmic strategy for high Lp(a) screening. Nature Cardiovascular Research 2024, 3: 558-566. PMID: 39195936, PMCID: PMC12190734, DOI: 10.1038/s44161-024-00469-1.Peer-Reviewed Original ResearchElectronic health recordsAssociated with premature atherosclerotic cardiovascular diseaseElevated Lp(aHealth recordsUK BiobankPremature atherosclerotic cardiovascular diseaseMachine learning modelsAtherosclerotic cardiovascular diseaseCohort studyReal-world settingsTargeted screeningCardiovascular diseaseLearning modelsNovel targeted therapeuticsAlgorithmic strategiesCohortProbability thresholdScreeningClinical featuresValidation cohortElevated lipoproteinRisk inspectionARICLp(a
2023
Validation of the European SCORE2 models in a Canadian primary care cohort
Sud M, Sivaswamy A, Austin P, Abdel-Qadir H, Anderson T, Khera R, Naimark D, Lee D, Roifman I, Thanassoulis G, Tu K, Wijeysundera H, Ko D. Validation of the European SCORE2 models in a Canadian primary care cohort. European Journal Of Preventive Cardiology 2023, 31: 668-676. PMID: 37946603, PMCID: PMC11025037, DOI: 10.1093/eurjpc/zwad352.Peer-Reviewed Original ResearchPrimary care cohortAtherosclerotic cardiovascular diseaseLow-risk regionsCare cohortC-statisticOlder personsElectronic medical record dataLarge Canadian cohortMedical record dataYears of ageYoung personASCVD riskCanadian cohortCardiovascular diseaseOlder womenIndividuals 70Age groupsSCORE2CohortRecord dataWomenMenRiskPersonsDiseaseMultinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
Khera R, Dhingra L, Aminorroaya A, Li K, Zhou J, Arshad F, Blacketer C, Bowring M, Bu F, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Horban S, Lau W, Li J, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLemore M, Minty E, Morales D, Nagy P, Nishimura A, Ostropolets A, Pistillo A, Posada J, Pratt N, Reyes C, Ross J, Seager S, Shah N, Simon K, Wan E, Yang J, Yin C, You S, Schuemie M, Ryan P, Hripcsak G, Krumholz H, Suchard M. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Medicine 2023, 2: e000651. PMID: 37829182, PMCID: PMC10565313, DOI: 10.1136/bmjmed-2023-000651.Peer-Reviewed Original ResearchType 2 diabetes mellitusSecond-line treatmentCardiovascular risk groupsDiabetes mellitusCardiovascular diseaseAntihyperglycaemic drugsLine treatmentRisk groupsObservational Health Data SciencesGlucagon-like peptide-1 receptor agonistsElectronic health recordsSodium-glucose cotransporter 2 inhibitorsCalendar year trendsPeptide-1 receptor agonistsUS databaseOutcomes of patientsCotransporter 2 inhibitorsAdministrative claims databaseSecond-line drugsHealth recordsSodium-glucose cotransporter-2 inhibitorsMedication useMetformin monotherapyGuideline recommendationsOutcome measuresUse of Smart Devices to Track Cardiovascular Health Goals in the United States
Aminorroaya A, Dhingra L, Nargesi A, Oikonomou E, Krumholz H, Khera R. Use of Smart Devices to Track Cardiovascular Health Goals in the United States. JACC Advances 2023, 2: 100544. PMID: 38094515, PMCID: PMC10718569, DOI: 10.1016/j.jacadv.2023.100544.Peer-Reviewed Original ResearchHealth goalsRisk of cardiovascular diseaseCardiovascular risk factorsNationally representative Health Information National Trends SurveyHealth Information National Trends SurveyU.S. adultsCardiovascular diseaseNational Trends SurveyRisk factors of hypertensionDigital health interventionsCardiovascular health goalsHealth-related goalsRisk of CVDFactors of hypertensionU.S. adult populationCardiovascular risk managementHigher educational attainmentLow-income individualsSmart devicesTrends SurveyImprove careHealth interventionsNational estimatesRisk factorsSurvey participantsUse of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020
Dhingra L, Aminorroaya A, Oikonomou E, Nargesi A, Wilson F, Krumholz H, Khera R. Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020. JAMA Network Open 2023, 6: e2316634. PMID: 37285157, PMCID: PMC10248745, DOI: 10.1001/jamanetworkopen.2023.16634.Peer-Reviewed Original ResearchConceptsHealth Information National Trends SurveyUS adultsExacerbate disparitiesWearable device usersCardiovascular diseaseCardiovascular healthPopulation-based cross-sectional studySelf-reported cardiovascular diseaseCardiovascular disease risk factorsNational Trends SurveyOverall US adult populationCardiovascular risk factor profileSelf-reported accessAssociated with lower useUse of wearable devicesImprove cardiovascular healthLower household incomeLower educational attainmentUS adult populationRisk factor profileNationally Representative SampleCross-sectional studyProportion of adultsTrends SurveyWearable device data
2022
Unfavorable social determinants of health are associated with higher burden of financial toxicity among patients with atherosclerotic cardiovascular disease in the US: findings from the National Health Interview Survey
Valero-Elizondo J, Javed Z, Khera R, Tano M, Dudum R, Acquah I, Hyder A, Andrieni J, Sharma G, Blaha M, Virani S, Blankstein R, Cainzos-Achirica M, Nasir K. Unfavorable social determinants of health are associated with higher burden of financial toxicity among patients with atherosclerotic cardiovascular disease in the US: findings from the National Health Interview Survey. Archives Of Public Health 2022, 80: 248. PMID: 36474300, PMCID: PMC9727868, DOI: 10.1186/s13690-022-00987-z.Peer-Reviewed Original ResearchFinancial toxicityEconomic stabilityNational Health Interview SurveyFood povertyCost-effective interventionHealth Interview SurveyCumulative social disadvantageMedical billsForegone careCost-related medicationComprehensive measureCardiovascular diseaseFinancial strainSocial determinantsInterview SurveyAtherosclerotic cardiovascular diseaseAge-stratified analysisNeighborhood conditionsDeterminantsSpecific social determinantsVulnerable groupsIncomeSDOH domainsHigh burdenHigher odds
2021
Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation Cardiovascular Quality And Outcomes 2021, 14: e008381. PMID: 34779654, PMCID: PMC9022137, DOI: 10.1161/circoutcomes.121.008381.Peer-Reviewed Original ResearchConceptsType 2 diabetesMedicare beneficiariesSodium-glucose cotransporter 2 inhibitorsLarge randomized clinical trialsMedicare Part D prescriber dataChronic kidney diseaseCotransporter 2 inhibitorsAtherosclerotic cardiovascular diseasePercent of cliniciansRandomized clinical trialsUS Medicare beneficiariesAdvanced practice providersCross-sectional studyKidney outcomesSGLT2i useSulfonylurea prescriptionUnique cliniciansCardiovascular deathMedication classesKidney diseaseLabel indicationsClinical trialsSGLT2iCardiovascular diseasePractice providersDigital Cardiovascular Epidemiology—Ushering in a New Era Through Computational Phenotyping of Cardiovascular Disease
Khera R. Digital Cardiovascular Epidemiology—Ushering in a New Era Through Computational Phenotyping of Cardiovascular Disease. JAMA Network Open 2021, 4: e2135561. PMID: 34807263, DOI: 10.1001/jamanetworkopen.2021.35561.Commentaries, Editorials and LettersConceptsCardiovascular diseaseScope and Social Determinants of Food Insecurity Among Adults With Atherosclerotic Cardiovascular Disease in the United States
Mahajan S, Grandhi GR, Valero‐Elizondo J, Mszar R, Khera R, Acquah I, Yahya T, Virani SS, Blankstein R, Blaha MJ, Cainzos‐Achirica M, Nasir K. Scope and Social Determinants of Food Insecurity Among Adults With Atherosclerotic Cardiovascular Disease in the United States. Journal Of The American Heart Association 2021, 10: e020028. PMID: 34387089, PMCID: PMC8475063, DOI: 10.1161/jaha.120.020028.Peer-Reviewed Original ResearchConceptsHigh-risk characteristicsUS adultsNational Health Interview Survey dataHealth Interview Survey dataAtherosclerotic cardiovascular diseaseCoronary heart diseaseSelf-reported diagnosisNon-Hispanic blacksInterview Survey dataFood Security Survey ModuleCardiovascular disease resultsLow family incomeAdult Food Security Survey ModuleFood insecurityHeart diseaseASCVDCardiovascular diseasePocket healthcare expenditureHigher oddsSociodemographic determinantsDisease resultsStudy participantsSocial determinantsHealthcare expendituresSociodemographic subgroupsAtherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States
Valero-Elizondo J, Chouairi F, Khera R, Grandhi GR, Saxena A, Warraich HJ, Virani SS, Desai NR, Sasangohar F, Krumholz HM, Esnaola NF, Nasir K. Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States. JACC CardioOncology 2021, 3: 236-246. PMID: 34396329, PMCID: PMC8352280, DOI: 10.1016/j.jaccao.2021.02.006.Peer-Reviewed Original ResearchCost-related medication nonadherenceFinancial toxicityMedication nonadherenceNational Health Interview SurveyAtherosclerotic cardiovascular diseaseMedical billsHealth Interview SurveyCancer careASCVDCardiovascular diseaseHigh burdenHigher oddsElderly populationCancerInterview SurveyFood insecurityCareNonadherenceSignificant proportionAdultsToxicityHigh financial distressPatientsPrevalenceDiseaseContemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply